X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DR. REDDYS LAB - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DR. REDDYS LAB DISHMAN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 25.1 24.8 101.1% View Chart
P/BV x 3.3 3.5 97.0% View Chart
Dividend Yield % 0.7 0.8 86.9%  

Financials

 DISHMAN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DR. REDDYS LAB
Mar-18
DISHMAN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3742,788 13.4%   
Low Rs1291,902 6.8%   
Sales per share (Unadj.) Rs197.8860.8 23.0%  
Earnings per share (Unadj.) Rs21.257.1 37.2%  
Cash flow per share (Unadj.) Rs34.7122.0 28.5%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.80.9 93.2%  
Book value per share (Unadj.) Rs179.9757.7 23.7%  
Shares outstanding (eoy) m80.69165.91 48.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.7 46.7%   
Avg P/E ratio x11.941.1 28.9%  
P/CF ratio (eoy) x7.219.2 37.7%  
Price / Book Value ratio x1.43.1 45.2%  
Dividend payout %9.435.0 26.9%   
Avg Mkt Cap Rs m20,306389,034 5.2%   
No. of employees `0000.823.5 3.5%   
Total wages/salary Rs m5,35532,149 16.7%   
Avg. sales/employee Rs Th19,252.76,070.8 317.1%   
Avg. wages/employee Rs Th6,459.51,366.6 472.7%   
Avg. net profit/employee Rs Th2,064.1402.5 512.8%   
INCOME DATA
Net Sales Rs m15,961142,810 11.2%  
Other income Rs m2651,552 17.1%   
Total revenues Rs m16,226144,362 11.2%   
Gross profit Rs m4,10323,512 17.5%  
Depreciation Rs m1,09110,772 10.1%   
Interest Rs m944788 119.8%   
Profit before tax Rs m2,33413,504 17.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m1344 0.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6244,380 14.2%   
Profit after tax Rs m1,7119,468 18.1%  
Gross profit margin %25.716.5 156.2%  
Effective tax rate %26.732.4 82.4%   
Net profit margin %10.76.6 161.7%  
BALANCE SHEET DATA
Current assets Rs m11,018104,984 10.5%   
Current liabilities Rs m9,51768,938 13.8%   
Net working cap to sales %9.425.2 37.3%  
Current ratio x1.21.5 76.0%  
Inventory Days Days11074 148.6%  
Debtors Days Days35104 33.6%  
Net fixed assets Rs m16,304104,385 15.6%   
Share capital Rs m161830 19.4%   
"Free" reserves Rs m12,907124,886 10.3%   
Net worth Rs m14,516125,716 11.5%   
Long term debt Rs m4,18925,089 16.7%   
Total assets Rs m29,805225,443 13.2%  
Interest coverage x3.518.1 19.1%   
Debt to equity ratio x0.30.2 144.6%  
Sales to assets ratio x0.50.6 84.5%   
Return on assets %8.94.5 195.8%  
Return on equity %11.87.5 156.5%  
Return on capital %17.59.7 180.6%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95272,623 6.8%   
Fx outflow Rs m69718,916 3.7%   
Net fx Rs m4,25553,707 7.9%   
CASH FLOW
From Operations Rs m2,78618,030 15.5%  
From Investments Rs m-1,529-14,883 10.3%  
From Financial Activity Rs m-941-4,440 21.2%  
Net Cashflow Rs m316-1,236 -25.6%  

Share Holding

Indian Promoters % 61.4 25.5 240.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.4 68.5%  
FIIs % 12.7 35.3 36.0%  
ADR/GDR % 0.0 18.5 -  
Free float % 22.1 15.3 144.4%  
Shareholders   46,261 75,885 61.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Marginally Lower; Consumer Durables & Energy Stocks Drag(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. US stocks rallied on Friday with the Dow and the Nasdaq posting eighth straight weekly gains.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)

Feb 5, 2019

A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - ABBOTT INDIA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS